

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number
WO 02/064118 A1(51) International Patent Classification⁷: A61K 9/16,
9/22, 9/52, 47/00, A61P 1/04SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/SE02/00227

(22) International Filing Date: 8 February 2002 (08.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0100477-9 13 February 2001 (13.02.2001) SE
0100478-7 13 February 2001 (13.02.2001) SE(71) Applicant (for all designated States except US): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): JUPPO, Anne
[FI/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal
(SE).(74) Agents: ASTRAZENECA AB et al.; Global Intellectual
Property, S-151 88 Södertälje (SE).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL MODIFIED RELEASE FORMULATION

(57) Abstract: The present invention is directed to a multiparticulate, modified release solid dispersion formulation, comprising a drug substance having a pH-dependent solubility, said drug substance being a compound of the formula I, or a pharmaceutically acceptable salt thereof; a hydrophobic matrix former which is a water-insoluble, non-swelling amphiphilic lipid; and a hydrophilic matrix former which is a meltable, water-soluble excipient; wherein the weight ratio hydrophobic matrix former/hydrophilic matrix former is ≥ 1 ; and the particle size is less than 300 μm . Also a unit dosage of the same, as well as a process for the preparation thereof and the use of the formulation and unit dosage is claimed.

WO 02/064118 A1

NOVEL MODIFIED RELEASE FORMULATION

Field of the Invention

5 The present invention is directed to a multiparticulate, modified release solid dispersion formulation, to a unit dosage of the same, as well as to a process for the preparation thereof. The invention also concerns the use of a multiparticulate, modified release solid dispersion formulation for the manufacture of a medicament for the treatment of gastric acid related diseases.

10

Background of the invention

Solubility of a drug in the gastrointestinal fluids and its permeability through the cell membrane determines its oral bioavailability (*Leuner and Dressman, Eur. J. Pharm. Biopharm 50, (2000) 47-60*). For drugs with low aqueous solubility, the dissolution rate in the lumen is the rate-limiting step. Particle size reduction, solubilization, and salt formation are commonly used formulation methods to improve the dissolution rate. However, there are limitations to each of these techniques.

20 Many drugs do not only have low water solubility, but they might also have a narrow therapeutical index, which means that the drug levels in the blood have to be carefully controlled. This can be achieved by a controlled release formulation. They have other benefits compared to regular dosage forms; patient acceptability is usually better due to fewer doses per day, and the drug is usually more efficiently used so less active drug is
25 needed.

Gel matrix tablets is a common drug form for modified release. The release rate is controlled either by erosion or by the diffusion of drug molecules in the swelled polymer matrix, which is the reason why drug solubility in the matrix material has great influence on the release rate. One disadvantage of matrix tablets is also that they cannot always be
5 divided, whereas multiparticulate tablets can be divided.

Solid dispersions have been studied as a possibility to control the drug release rate (*Aceves et al., Int. J. Pharm.* 195, (2000) 45-53). Solid dispersion is a dispersion of one or more active ingredients in an inert carrier or matrix at solid state, prepared by the melting
10 (fusion), solvent or melting-solvent method (*Chiou and Riegelman., J. Pharm. Sci.* 60, (1971) 1281-1302). In *J. Pharm. Sci.* 58, (1969) 1505-1509, *Chiou and Riegelman* have classified the solid dispersions into following groups: Eutetic mixtures; solid solutions; glass solutions and glass suspensions; amorphous precipitations in crystalline carrier; and combinations of those above.

15 Melt processing (fusion method) was presented for the first time by *Segikuchi, K. and Obi, N.* in 1961, in *Chem. Pharm. Bull.* 9 (1961), 866-872 to prepare solid dispersions. In the melt method a physical mixture of the carrier and the drug is melted and then solidified. Cooling leads to supersaturation, but due to solidification the dispersed drug is trapped in
20 to the carrier matrix. Melt method is often recommended, because no organic solvents are needed, so it is often less costly and better for the environment than the solvent method. However, it is not a suitable manufacturing method for thermolabile drugs. Thermal degradation, sublimation and polymorphic transformations may also occur during fusion (*Goldberg et al, J. Pharm. Sci.* 54, (1965) 1145-1148).

25 The principle of solid dispersions has been used in many pharmaceutical formulations, mostly in order to increase the bioavailability but in some cases for obtaining sustained release. Solid dispersions can be prepared of lipophilic matrix materials. The release rate is adjusted by varying the drug-exipient ratio. The amount of drug released increases with
30 increased loading (*Bodmeier et al, Drug. Dev. Ind. Pharm.* 16 (9), (1990) 1505-1519).

Besides waxes and polar lipids, different polymers have been used to control drug release rate from solid dispersions. *Ozeki et al.* have shown that the release rate of phenacetin from a solid dispersion composed of poly(ethylene oxide)-carboxyvinylpolymer interpolymer complex can be controlled (*Ozeki et al., J. Control. Release* 58, (1999) 87-95).

5

US 6, 132, 772 (corresponding to WO 96/23499) discloses an oral, extended release solid pharmaceutical composition comprising polyethylene glycol having a molecular weight of at least 1000, a drug having a solubility of less than 0.1 % by weight in water at 20 °C and a hydrophilic gel-forming polymer having a mean molecular weight of at least 20 000.

10

US 5,965,163 discloses a solid dosage form comprising a plurality of particles. The drug may according to this document be soluble or water insoluble.

15

US 5,405,617 discloses the preparation of carrier matrices and spray congealed powders comprising an admixture of aliphatic or fatty acid esters and pharmaceutical actives which can be compressed into tablet and caplet dosage form.

US 4,629,621 discloses a sustained release preparation of bioactive material having erodible characteristics.

20

Stearic acid (C-18) is the most commonly used of the fatty acids in pharmaceutical products. In oral pharmaceutical formulations, it is mainly used as a tablet lubricant in small concentrations and as a binder (*The Handbook of Pharmaceutical Excipients*, 3rd Ed. *AphA*, (2000) 665). Stearic acid has also been used as a controlled release matrix excipient in spray congealing (*Rodriguez et al., Int. J. Pharm.* 183, (1999) 133-143). The drug substances used by Rodriguez were theophylline having a water solubility at 25 °C of 8.3 mg/ml, and fenbufen having a water solubility at 25 °C of 0.11 mg/ml.


30

Outline of the invention

The object of the present invention is to provide a pharmaceutical formulation of a drug substance having a pH-dependent solubility in water.

More particularly, the present invention is directed to a multiparticulate, modified release solid dispersion formulation, comprising

(i) a drug substance having a pH-dependent solubility, said drug substance being a compound of the formula I



or a pharmaceutically acceptable salt thereof, wherein

R¹ is

- (a) H,
- (b) CH₃, or
- (c) CH₂OH;

R² is

- (a) CH₃
- (b) CH₂CH₃

R³ is

- (a) H

- (b) C₁-C₆ alkyl,
- (c) hydroxylated C₁-C₆ alkyl
- (d) halogen

5

R⁴ is

- (a) H,
- (b) C₁-C₆ alkyl,
- (c) hydroxylated C₁-C₆ alkyl, or
- (d) halogen;

10

R⁵ is

- (a) H, or
- (b) halogen;

15

R⁶ and R⁷ are the same or different, selected from any one of

- (a) H,
- (b) C₁-C₆ alkyl;
- (c) hydroxylated C₁-C₆ alkyl
- (d) C₁-C₆ alkoxy-substituted C₁-C₆ alkyl

20

X is

- (a) NH, or
- (b) O;

25

(ii) at least one hydrophobic matrix former which is a meltable, non-swelling amphiphilic lipid having a water-solubility below 1 mg/g; and

(iii) at least one hydrophilic matrix former which is a meltable excipient having a water-solubility above 0.1 g/g;

30

wherein

the weight ratio hydrophobic matrix former/ hydrophilic matrix former is ≥ 1 ; and
the particle size is less than 300 μm .

The term "modified release" is herein defined as a formulation that releases less than 90% if its drug contents during the first three hours of the release.

The wording "at least one hydrophobic matrix former" as used herein, is defined such that
5 one hydrophobic matrix former can be used alone, or in an alternative embodiment of the invention a mixture of hydrophobic matrix formers may be used.

The wording "at least one hydrophilic matrix former" as used herein, is defined such that
10 one hydrophilic matrix former can be used alone, or in an alternative embodiment of the invention a mixture of hydrophilic matrix formers may be used.

The term "solid dispersion" is herein defined as a dispersion of the active compound of the formula I in an inert carrier or matrix at solid state. Solid dispersions are more particularly defined herein as eutetic mixtures, solid solutions, glass solutions or glass suspensions,
15 amorphous precipitations in crystalline carrier or combinations thereof.

The solubility of the substances used in accordance with the present invention is pH-dependent. The wording "pH-dependent solubility" is in accordance with the present invention defined so as that the solubility of the drug substance in water is higher in lower
20 pH, and lower in higher pH, more specifically at least 2 mg/ml at $\text{pH} \leq 2$ and lower than 1 mg/ml at $\text{pH} \geq 4$ at room temperature, i.e. at a temperature of about 23 -25°C.

The wording "multiparticulate formulation" as used in accordance with the present invention is defined as a formulation comprising individual units of the drug substance, the
25 hydrophobic matrix former and the hydrophilic matrix former, compressed into e.g. one single tablet.

The hydrophobic matrix formers are in accordance with the present invention water-insoluble, non-swelling fatty acids having a melting point above 50 °C, more particularly a

melting point up to 55 °C. Examples of a specific fatty acid useful in accordance with the present invention is myristic acid.

The hydrophilic matrix formers are in accordance with the present invention meltable,
5 water soluble excipients which are solid at room temperature, such as polyethylene oxides; polyethylene glycols; and polyethylene oxide and polypropylene oxide block-co-polymers, e.g. poloxamers. Specific examples of poloxamers useful in accordance with the present invention are poloxamer 188, also known under the trade name Pluronic F68[®], and poloxamer 407, which is also known under the trade name Pluronic F127[®]. Pluronic F68[®]
10 and Pluronic F127[®] are commercially available from BASF. Specific examples of polyethylene glycols useful in accordance with the present invention are PEG 4000, known under the trade name Macrogol 4000[®], and PEG 6000, known under the trade name Macrogol 6000[®]. Any poloxamer and PEG which are solid at room temperature may be used in accordance with the present invention. A comprehensive list of poloxamers and
15 PEG's useful in accordance with the present invention can be found in *Handbook of Pharmaceutical Excipients 3rd Ed., American Pharmaceutical Association and Pharmaceutical Press (2000), Washington, 665*, which is hereby incorporated by reference, but which list however should not in any way be interpreted as exhaustive. Also other hydrophilic excipients which are miscible with the hydrophobic matrix formers as
20 melts are useful in accordance with the present invention.

The weight ratio of hydrophobic matrix former/ hydrophilic matrix former is ≥ 1 , the excess amount of the hydrophobic matrix providing a sustained release effect.

25 In one embodiment of the invention, the total amount of the compound of the formula I is below about 40 % by weight. In a further aspect of the invention the total amount of the compound of the formula I is 30-40 % by weight, and in still a further embodiment of the invention the total amount of the compound of the formula I is 20-30 % by weight.

The wording "unit dosage form" is herein defined as a composition where the amount of active compound of the formula I is administered as one single tablet, capsule or other suitable form in accordance with the present invention.

- 5 As used herein, the term "C₁-C₆ alkyl" denotes a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of said C₁-C₆ alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl.

- 10 The term "halogen" includes fluoro, chloro, bromo and iodo.

As the drug substance used in accordance with the present invention are both the pure enantiomers, racemic mixtures and unequal mixtures of two enantiomers. It should be understood that all the diastereomeric forms possible (pure enantiomers, racemic mixtures and unequal mixtures of two enantiomers) are within the scope of the present invention as the active drug substance, as well as derivatives of the compounds of the Formula I which have the biological function of the compounds of the Formula I, such as prodrugs.

It will also be appreciated by those skilled in the art, although derivatives of compounds of formula I may not possess pharmacological activity as such, they may be administered orally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". Prodrugs of compounds of formula I are also within the scope of the invention. Depending on the process conditions the end products of the Formula I are obtained either in neutral or salt form. Both the free base and the salts of these end products are within the scope of the invention.

In one aspect of the invention, the active drug substance is a compound of the formula I wherein R¹ is CH₃ or CH₂OH; R² is CH₃ or CH₂CH₃; R³ is CH₃ or CH₂CH₃; R⁴ is CH₃ or CH₂CH₃; R⁵ is H, Br, Cl, or F.

In a further aspect of the present invention, the active drug substance of the formula I is a compound selected from any one of

- 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-propyl-imidazo[1,2-a]pyridine-6-carboxamide;
- 5 • 8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethyl-2-methylimidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-
10 carboxamide;
- 8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide;
- 8-(2-ethyl-6-methylbenzylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide;
- 15 • 2,3-dimethyl-8-(2,6-dimethylbenzyl-amino)-imidazo[1,2-a]pyridine-6-carboxamide, N-[2-(dimethylamine)-2-oxoethyl]-8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate;
- 20 • 2,3-dimethyl-8-(2-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide; 2,3-dimethyl-8-(2,6-dimethyl-4-fluoro-benzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate;
- 2,3-dimethyl-8-(2-methyl-6-isopropylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate;
- 25 • 2,3-dimethyl-8-(2,6-diethyl-benzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2-ethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3 dimethyl-8-(2-ethyl-6-methyl-benzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide;
- N-(2,3-dihydroxypropyl)-2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-[1,2-
30 a]pyridine-6-carboxamide;

- 2,3 dimethyl-8-(2-ethyl-6-methyl-benzylamino)-N-(2-methoxyethyl)-imidazo[1,2-a]pyridine-6-carboxamide;
- 2-methyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2-bromo-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2-(2-hydroxyethyl)-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 8-(2-ethyl-6-methylbenzylamino)-N,N-bis(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide;
- 8-(2-ethyl-6-methylbenzylamino)-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide; and
- 2,3-dimethyl-8-(2-ethyl-6-methylbenzyloxy)-imidazo[1,2-a]pyridine-6-carboxamide; or a pharmaceutically acceptable salt thereof.

In still a further aspect of the present invention, the active drug substance of the formula I is a compound selected from any one of

- 8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethyl-2-methylimidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2,6-dimethyl-4-fluoro-benzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2,6-diethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;

- 2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide; and
- 2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-(2-methoxyethyl)-imidazo[1,2-a]pyridine-6-carboxamide; or a pharmaceutically acceptable salt thereof.

5

Compounds of the formula I above and their preparation, are described in the patent application PCT/SE99/00663 (WO 99/55706), which is hereby incorporated in full as reference.

10 The pharmaceutical formulation according to the present invention is useful particular for the inhibition of gastric acid secretion. Thus, one aspect of the present invention is the use of a multiparticulate, modified release formulation as claimed and described herein, for the manufacture of a medicament for the inhibition of gastric acid secretion.

15 Another aspect of the present invention, is a method for the inhibition of gastric acid secretion, whereby a multiparticulate, modified release formulation as claimed and described herein, is administered to a patient in need of such gastric acid secretion inhibition.

20 The typical daily dose of the active substance according to formula I above varies within a wide range and will depend on various factors such as for example the individual requirement of each patient and the disease. In general, the formulation according to the invention is administered orally, and dosages will be in the range of from 5 to 1000 mg per day of active substance.

25

The multiparticulate, modified release formulation according to the present invention may be formulated into a unit dosage form, preferably as a tablet, which may also comprise standard excipients known to the skilled person in the art of tablet formulation. Examples of such excipients are fillers, binders, disintegrants and lubricants, but this list should
30 however not be interpreted as being exhaustive.

The multiparticulate, modified release solid dispersion formulation according to the present invention provides the possibility of formulating drug substances of the formula I, said drug substances having a pH-dependent solubility in water. The novel formulation is particularly useful when formulated into a tablet, since it may also provide improved chances of dividing the tablet without disturbing the release rate of the active drug substance.

Methods of preparation

In spray congealing, or spray chilling as it is also called, the melted mass is atomized into droplets, which solidify quickly in cool air (*Killeen, Pharm. Eng., July/August 1993, 56-64*). The process differs from spray drying in that in spray drying the main action is evaporation of solvent caused by warm air, whereas in spray congealing it is a phase change from liquid to solid.

The spray congealing process used in accordance with the present invention comprises the following steps:

- (i) melting the hydrophobic matrix former;
- (ii) partially or totally dissolving, or emulsifying the compound of formula I into the melt;
- (iii) dissolving the hydrophilic matrix former into the melt;
- (iv) atomizing the melt into droplets;
- (v) solidifying the droplets; and
- (vi) collecting the particles.

The produced particles can then be further formulated into tablets or filled into capsules.

By the wording "partially or totally dissolving" in the method step (ii) above, it should be understood that a slight amount of the compound may remain undissolved in the melt.

The atomization into droplets can be done with different techniques, such as with a capillary nozzle, with a pneumatic nozzle, with an ultrasonic nozzle, with a hydraulic

nozzle, with electrospraying, with rotary atomization, and preferably with a pneumatic nozzle using warm air as atomization gas.

The solidification of droplets can take place in liquid nitrogen, in or on carbondioxide ice
5 or in air with a temperature lower than the melting point of the droplets. The particles may be collected into a vessel directly, or with a cylinder connected to a cyclone. The resulted particles are smaller than 300 μm , preferably spherical. The drug is in the particles present in the form of a solid dispersion.

10 Additives may be added into the melt prior to the atomization. Examples of such additives are surface active agents, excipients increasing viscosity, and buffering agents, but this list should however not in any way be interpreted as limiting the invention.

Detailed description of the invention

15

The invention will now be described in more detail by way of the following examples, which however should not be construed as limiting the invention in any way.

The following multiparticulate, modified release solid dispersion formulations were
20 prepared.

Example 1

	<u>amount [g]</u>
(i) 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)imidazo[1,2-a]-pyridine-6-carboxamide mesylate	1
(ii) myristic acid	4
5 (iii) PEG 4000	2

I. Preparation of the multiparticulate, modified release formulation

2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)imidazo[1,2-a]-pyridine-6-carboxamide mesylate (1 g) was dissolved in a melt of 4 g myristic acid at 90°C. The amount of 2 g
10 polyethylene glycol 4000 (PEG 4000) was added into the melt. The melted mixture was kept at 90°C and atomized with a pneumatic nozzle having an inner diameter of 1 mm and by using atomization air temperature of 400°C and a pressure of 7 bar. The particles were collected into a vessel which was kept on carbondioxide ice (temperature -50°C).

15 The resulted particles were spherical and smaller than 300 µm in size, as seen in Scanning Electron Micrograph (SEM).

II. Tabletting

The amount of 3 g of particles prepared in step I above, were blended with 5.85 g
20 microcrystalline cellulose and 0.016 g sodium stearyl fumarate in a Turbula mixer of the type 72C, Willy A. Bachofen AG Maschinenfabrik, Basle, Switzerland, for 10 minutes. This mixture was compressed by using an excentric tablet press Korsch EK-0 into 450 mg tablets using 11.3 mm flat punches with a maximum compression force of 5.0-5.6 kN. The breaking force of resulting tablets was measured by using a Schleuniger tablet
25 hardness tester 4M, Dr. Schleuniger Productronic AG, Solothurn, Switzerland. The breaking force of resulting tablets was within the range 139-168 N.

The dissolution of tablets was tested with USP II paddle method in 900 ml 0.1M HCl with 50 rpm. The amount dissolved in 3 hours was from 52-56%.

Example 2

	<u>amount [g]</u>
(i) 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)imidazo[1,2-a]-pyridine-6-carboxamide mesylate	1
5 (ii) myristic acid	4
(iii) PEG 4000	2

I. Preparation of the multiparticulate, modified release formulation

2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)imidazo[1,2-a]-pyridine-6-carboxamide
10 mesylate (1 g) was dissolved in a melt of 4 g myristic acid at 90°C. The amount of 2 g
polyethylene glycol 4000 (PEG 4000) was added into the melt. The melted mixture was
kept at 90°C and atomized with a pneumatic nozzle having an inner diameter of 1 mm and
by using atomization air temperature of 400°C into a cylinder in room temperature. The
cylinder was connected to a cyclone, which was used to collect the particles.

15


The resulted particles were spherical and smaller than 300 µm in size, as seen in Scanning
Electron Micrograph (SEM).

20

Claims

1. A multiparticulate, modified release solid dispersion formulation, comprising

(i) a drug substance having a pH-dependent solubility, said drug substance being a compound of the formula I



or a pharmaceutically acceptable salt thereof, wherein

R^1 is

- (a) H,
- (b) CH_3 , or
- (c) CH_2OH ;

R^2 is

- (a) CH_3
- (b) CH_2CH_3

R^3 is

- (a) H
- (b) C_1 - C_6 alkyl,
- (c) hydroxylated C_1 - C_6 alkyl
- (d) halogen

R^4 is

- (a) H,
- (b) C_1-C_6 alkyl,
- (c) hydroxylated C_1-C_6 alkyl, or
- 5 (d) halogen;

R^5 is

- (a) H, or
- (b) halogen;

10 R^6 and R^7 are the same or different, selected from any one of

- (a) H,
- (b) C_1-C_6 alkyl;
- (c) hydroxylated C_1-C_6 alkyl
- 15 (d) C_1-C_6 alkoxy-substituted C_1-C_6 alkyl

X is

- (a) NH, or
- (b) O;

20 (ii) at least one hydrophobic matrix former which is a meltable, non-swelling amphiphilic lipid having a water-solubility below 1 mg/g; and

(iii) at least one hydrophilic matrix former which is a meltable excipient having a water-
25 solubility above 0.1 g/g;

wherein

the weight ratio hydrophobic matrix former/ hydrophilic matrix former is ≥ 1 ; and

30 the particle size is less than 300 μm .

2. A multiparticulate, modified release solid dispersion formulation according to claim 1, wherein the solubility of the drug substance in water is at least 2 mg/ml at $\text{pH} \leq 2$ and at room temperature.

5

3. A multiparticulate, modified release solid dispersion formulation according to claim 1, wherein the solubility of the drug substance in water is lower than 1 mg/ml at $\text{pH} \geq 4$ and at room temperature.

10 4. A multiparticulate, modified release solid dispersion formulation according to any one of claims 1-3, wherein the hydrophobic matrix former or mixture thereof, is a water-insoluble, non-swelling fatty acid having a melting point above 50 °C.

15 5. A multiparticulate, modified release solid dispersion formulation according to any one of claims 1-3, wherein the hydrophobic matrix former or mixture thereof, is a water-insoluble, non-swelling fatty acid having a melting point of up to 55 °C.

20 6. A multiparticulate, modified release solid dispersion formulation according to any one of the preceding claims, wherein the hydrophobic matrix former or mixture thereof, comprises myristic acid.

25 7. A multiparticulate, modified release solid dispersion formulation according to any one of claims 1-6, wherein the hydrophilic matrix former or mixture thereof, is selected from any one of polyethylene oxides, polyethylene glycols, polyethylene oxide and polypropylene oxide block-co-polymers.

8. A multiparticulate, modified release solid dispersion formulation according to claim 7, wherein the hydrophilic matrix former is a poloxamer.

9. A multiparticulate, modified release solid dispersion formulation according to any one of the preceding claims, wherein the hydrophilic matrix former is a polyethylene glycol.

5 10. A multiparticulate, modified release solid dispersion formulation according to claim 7, wherein the hydrophilic matrix former or mixture thereof, is selected from PEG 4000 and PEG 6000.

11. A multiparticulate, modified release solid dispersion formulation according to any one
10 of the preceding claims, wherein R^1 is CH_3 or CH_2OH ; R^2 , R^3 and R^4 independently are CH_3 or CH_2CH_3 ; and R^5 is H, Br, Cl, or F.

12. A multiparticulate, modified release solid dispersion formulation according to any one of the preceding claims, wherein the compound of formula I is any one selected from

15

- 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-propyl-imidazo[1,2-a]pyridine-6-carboxamide;
- 8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethyl-2-methylimidazo[1,2-a]pyridine-6-carboxamide;
- 20 • 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-
- 25 carboxamide;
- 8-(2-ethyl-6-methylbenzylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2,6-dimethylbenzyl-amino)-imidazo[1,2-a]pyridine-6-carboxamide, N-[2-(dimethylamine)-2-oxoethyl]-8-(2-ethyl-6-methylbenzylamino)-N,2,3-
- 30 trimethylimidazo[1,2-a]pyridine-6-carboxamide;

- 2,3-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate;
 - 2,3-dimethyl-8-(2-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
 - 2,3-dimethyl-8-(2,6-dimethyl-4-fluoro-benzylamino)-imidazo[1,2-a]pyridine-6-
 - 5 carboxamide mesylate;
 - 2,3-dimethyl-8-(2-methyl-6-isopropylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate;
 - 2,3-dimethyl-8-(2,6-diethyl-benzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
 - 2,3-dimethyl-8-(2-ethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
 - 10 • 2,3 dimethyl-8-(2-ethyl-6-methyl-benzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide;
 - N-(2,3-dihydroxypropyl)-2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-[1,2-a]pyridine-6-carboxamide;
 - 2,3 dimethyl-8-(2-ethyl-6-methyl-benzylamino)-N-(2-methoxyethyl)-imidazo[1,2-
 - 15 a]pyridine-6-carboxamide;
 - 2-methyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
 - 2,3-dimethyl-8-(2-bromo-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
 - 2,3-dimethyl-8-(2-(2-hydroxyethyl)-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-
 - 20 carboxamide;
 - 8-(2-ethyl-6-methylbenzylamino)-N,N-bis(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide;
 - 8-(2-ethyl-6-methylbenzylamino)-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide; and
 - 25 • 2,3-dimethyl-8-(2-ethyl-6-methylbenzyloxy)-imidazo[1,2-a]pyridine-6-carboxamide;
- or a pharmaceutically acceptable salt thereof.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

13. A multiparticulate, modified release formulation according to claim 12, wherein the compound is any one selected from

- 5 • 8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethyl-2-methylimidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 10 • 8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 15 • 2,3-dimethyl-8-(2,6-dimethyl-4-fluoro-benzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3-dimethyl-8-(2,6-diethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide;
- 2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide; and
- 20 • 2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-(2-methoxyethyl)-imidazo[1,2-a]pyridine-6-carboxamide; or a pharmaceutically acceptable salt thereof.

14. A multiparticulate, modified release solid dispersion formulation according to any one of the preceding claims, wherein the compound of formula I is in the form of a
25 hydrochloride or mesylate salt.

15. A multiparticulate, modified release solid dispersion formulation according to any one of the preceding claims, wherein the total amount of the drug substance of formula I of claim 1, is below about 40 % by weight.

16. A unit dosage form comprising a multiparticulate, modified release solid dispersion formulation according to any one of claims 1-15.

17. A tablet comprising a multiparticulate, modified release solid dispersion formulation
5 according to any one of claims 1-15, optionally further comprising one or more pharmaceutically acceptable excipients.

18. A tablet according to claim 17, said excipients being microcrystalline cellulose and sodium stearyl fumarate.

10

19. A process for the preparation of a multiparticulate, modified release formulation according to any one of claims 1-15, whereby said formulation is prepared by spray
congealing.

15 20. A process according to claim 19, whereby the spray congealing comprises the following steps:

- (i) melting the hydrophobic matrix former;
- (ii) partially or totally dissolving, or emulsifying, the compound of formula I into the melt;
- 20 (iii) dissolving the hydrophilic matrix former into the melt;
- (iv) atomizing the melt into droplets;
- (v) solidifying the droplets; and
- (vi) collecting the particles.

25

21. Use of a multiparticulate, modified release solid dispersion formulation according to any one of claims 1-15, for the manufacture of a medicament for the inhibition of gastric acid secretion.

22. A method for the inhibition of gastric acid secretion, whereby a multiparticulate, modified release solid dispersion formulation according to any one of claims 1-15, is administered to a patient in need of such gastric acid secretion inhibition.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/00227

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 9/16, A61K 9/22, A61K 9/52, A61K 47/00, A61P 1/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4629621 A (SNIPES), 16 December 1986 (16.12.86) --	1-22
X	US 5965163 A (MILLER ET AL), 12 October 1999 (12.10.99) --	1-22
A	GB 907310 A (ABBOTT LABORATORIES), 3 October 1962 (03.10.62) --	1-22
A	EP 0387885 A2 (BRISTOL-MYERS COMPANY), 19 Sept 1990 (19.09.90) --	1-22

☒ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
---	---

Date of the actual completion of the international search

7 May 2002

Date of mailing of the international search report

04-06-2002

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

EVA JOHANSSON/BS
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/00227

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9955705 A1 (ASTRA AKTIEBOLAG), 4 November 1999 (04.11.99) --	1-22
A	WO 9955706 A1 (ASTRA AKTIEBOLAG), 4 November 1999 (04.11.99) -- -----	1-22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE02/00227

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 22
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE02/00227

Claim 22 relates to a method of treatment of the human or animal body by surgery or by therapy/a diagnostic method practised on the human or animal body/Rule 39.1(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT
Information on patent family members

28/01/02

International application No.

PCT/SE 02/00227

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
US	4629621	A	16/12/86	AU	573149 B	26/05/88
				AU	4638885 A	25/02/86
				CA	1246448 A	13/12/88
				DE	3586823 A,T	17/12/92
				EP	0190255 A,B	13/08/86
				JP	61502759 T	27/11/86
				US	4744976 A	17/05/88
				US	4774074 A	27/09/88
				US	4806337 A	21/02/89
				US	5082655 A	21/01/92
				WO	8600802 A	13/02/86

INTERNATIONAL SEARCH REPORT
Information on patent family members

28/01/02

International application No.

PCT/SE 02/00227

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5965163 A	12/10/99	US 6162467 A	19/12/00
		US 2001019725 A	06/09/01
		AT 212224 T	15/02/02
		AU 682223 B	25/09/97
		AU 7901594 A	01/06/95
		BG 62429 B	30/11/99
		BG 99198 A	28/08/95
		CN 1116521 A	14/02/96
		CZ 9402866 A	14/06/95
		DE 69429710 D	00/00/00
		EP 0654263 A,B	24/05/95
		SE 0654263 T3	
		EP 0699436 A,B	06/03/96
		SE 0699436 T3	
		FI 945476 A	24/05/95
		HU 74910 A	28/03/97
		HU 217205 B	28/12/99
		HU 9403353 D	00/00/00
		IL 111709 D	00/00/00
		JP 7196475 A	01/08/95
		NO 944473 A	24/05/95
		NZ 264953 A	26/11/96
		SK 140694 A	11/07/95
		SK 280496 B	13/03/00
		US 5849240 A	15/12/98
		US 5891471 A	06/04/99
		AT 3413 U	27/03/00
		AT 138566 T	15/06/96
		AT 172376 T	15/11/98
		AT 201989 T	15/06/01
		AU 722358 B	27/07/00
		AU 3995797 A	18/12/97
		AU 5299598 A	26/03/98
		AU 6196394 A	17/11/94
		AU 6610594 A	12/01/95
		BG 62316 B	31/08/99
		BG 62473 B	30/12/99
		BG 99077 A	30/06/95
		BG 99078 A	28/07/95
		CA 2123160 A	11/11/94
		CA 2127166 A	02/01/95
		CZ 287918 B	14/03/01
		CZ 288517 B	11/07/01
		CZ 9401093 A	16/11/94
		CZ 9401550 A	18/01/95
		DE 699436 T	10/04/97
		DE 729751 T	13/03/97
		DE 9422335 U	13/04/00
		DE 69400215 D,T	31/10/96
		DE 69414046 D,T	22/04/99
		DE 69427472 D,T	08/11/01
		DK 624366 T	01/07/96
		DK 636370 T	28/06/99
		DK 699436 T	23/07/01
		EG 20577 A	30/08/99

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

28/01/02

PCT/SE 02/00227

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5965163 A	12/10/99	EG 20600 A	30/09/99
		EG 20910 A	28/06/00
		EP 0624366 A,B	17/11/94
		SE 0624366 T3	
		EP 0636370 A,B	01/02/95
		SE 0636370 T3	
		EP 0729751 A	04/09/96
		ES 2088312 T	01/08/96
		ES 2124372 T	01/02/99
		ES 2159591 T	16/10/01
		FI 942092 A	11/11/94
		FI 943141 A	02/01/95
		GB 2284760 A,B	21/06/95
		GB 9324045 D	00/00/00
		GR 3020084 T	31/08/96
		HU 70938 A	28/11/95
		HU 75703 A	28/05/97
		HU 220075 B	28/10/01
		HU 9401478 D	00/00/00
		HU 9402007 D	00/00/00
		IL 109460 A	10/03/98
		IL 109944 A	06/12/98
		IL 119660 D	00/00/00
		JP 3045924 B	29/05/00
		JP 7053361 A	28/02/95
		JP 7149648 A	13/06/95
		JP 11124327 A	11/05/99
		NO 306446 B	08/11/99
		NO 306449 B	08/11/99
		NO 941719 A	11/11/94
		NO 942470 A	02/01/95
		NO 993484 A	11/11/94
		NO 20013566 A	11/11/94
		NZ 260408 A	28/05/96
		NZ 260883 A	24/06/97
		PL 178883 B	30/06/00
		PL 179282 B	31/08/00
		PL 304062 A	09/01/95
		PL 305939 A	29/05/95
		PT 699436 T	30/10/01
		SG 50706 A	20/07/98
		SG 67347 A	21/09/99
		SK 54194 A	07/12/94
		SK 76394 A	09/08/95
		SK 279971 B	11/06/99
		SK 280534 B	13/03/00
		US 5591452 A	07/01/97
		US 5879705 A	09/03/99
		US 6143328 A	07/11/00
		US 6254887 B	03/07/01
		US 6326027 B	04/12/01
		US 2001036477 A	01/11/01
		ZA 9409296 A	08/08/95
		GB 2288117 A	11/10/95
		GB 9403922 D	00/00/00

INTERNATIONAL SEARCH REPORT
Information on patent family members

28/01/02

International application No.

PCT/SE 02/00227

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
US	5965163	A	12/10/99	GB 9404544 D	00/00/00
				PL 176474 B	30/06/99
				PL 177332 B	29/10/99
				AU 694475 B	23/07/98
				AU 1475595 A	21/09/95
				CA 2144500 A	15/09/95
				CN 1099262 A	01/03/95
				CN 1102323 A	10/05/95
				EP 0672416 A	20/09/95
				FI 951155 A	15/09/95
				GB 2287880 A	04/10/95
				GB 9404928 D	00/00/00
				JP 8040905 A	13/02/96
				NO 950950 A	15/09/95
				US 5843480 A	01/12/98
				ZA 9502013 A	11/12/95
				GB 9411842 D	00/00/00
GB	907310	A	03/10/62	BE 593354 A	00/00/00
				FR 1288725 A	30/03/62
				NL 248553 A	00/00/00

INTERNATIONAL SEARCH REPORT
 Information on patent family members

28/01/02

International application No.

PCT/SE 02/00227

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
EP	0387885	A2	19/09/90	SE 0387885 T3	
				AT 128031 T	15/10/95
				AU 617601 B	28/11/91
				AU 5136790 A	20/09/90
				BG 60501 B	30/06/95
				CA 2012300 A	16/09/90
				CN 1045921 A	10/10/90
				CN 1047935 B	05/01/00
				CS 277488 B	17/03/93
				DD 292837 A	14/08/91
				DE 69022452 D,T	14/03/96
				DK 0387885 T	06/11/95
				EG 19669 A	30/08/95
				ES 2078917 T	01/01/96
				FI 92464 B,C	15/08/94
				FI 901241 D	00/00/00
				GR 3017460 T	31/12/95
				HK 51396 A	29/03/96
				HU 54489 A	28/03/91
				HU 209958 B	28/12/94
				HU 901429 D	00/00/00
				IE 70591 B,L	11/12/96
				IL 93720 D	00/00/00
				JP 2974719 B	10/11/99
				JP 3236326 A	22/10/91
				KR 140211 B	01/06/98
				NO 176043 B,C	17/10/94
				NO 901183 D	00/00/00
				NZ 232864 A	28/04/92
				OA 9198 A	30/06/92
				PL 163301 B	31/03/94
				PT 93452 A,B	07/11/90
				RO 106953 A,B	30/08/93
				RU 2069558 C	27/11/96
				US 4956182 A	11/09/90
				US 5372823 A	13/12/94
				US 5455047 A	03/10/95
				YU 52390 A	31/10/91
				ZA 9002001 A	28/11/90
				ZW 1890 A	31/10/90

INTERNATIONAL SEARCH REPORT
 Information on patent family members

28/01/02

International application No.

PCT/SE 02/00227

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
WO	9955705	A1	04/11/99	AU 727349 B	14/12/00
				AU 4300699 A	16/11/99
				AU 4300799 A	16/11/99
				AU 9098998 A	22/03/99
				BR 9909995 A	26/12/00
				BR 9909996 A	26/12/00
				CA 2329921 A	04/11/99
				CA 2329922 A	04/11/99
				CN 1306533 T	01/08/01
				CN 1307577 T	08/08/01
				EP 1011653 A	28/06/00
				EP 1073656 A	07/02/01
				EP 1073657 A	07/02/01
				HU 0102313 A	28/12/01
				HU 0102425 A	28/11/01
				JP 2001514215 T	11/09/01
				NO 20001087 A	02/03/00
				NO 20005450 A	22/12/00
				NO 20005451 A	27/12/00
				PL 338982 A	04/12/00
				PL 343797 A	10/09/01
				PL 343801 A	10/09/01
				SE 9801526 D	00/00/00
				SK 14912000 A	11/06/01
				SK 14922000 A	11/06/01
				US 6245818 B	12/06/01
				US 6313136 B	06/11/01
				US 6313137 B	06/11/01
				WO 9955706 A	04/11/99

INTERNATIONAL SEARCH REPORT
 Information on patent family members

28/01/02

International application No.

PCT/SE 02/00227

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9955706 A1	04/11/99	AU 727349 B	14/12/00
		AU 4300699 A	16/11/99
		AU 4300799 A	16/11/99
		AU 9098998 A	22/03/99
		BR 9909995 A	26/12/00
		BR 9909996 A	26/12/00
		CA 2329921 A	04/11/99
		CA 2329922 A	04/11/99
		CN 1306533 T	01/08/01
		CN 1307577 T	08/08/01
		EP 1011653 A	28/06/00
		EP 1073656 A	07/02/01
		EP 1073657 A	07/02/01
		HU 0102313 A	28/12/01
		HU 0102425 A	28/11/01
		JP 2001514215 T	11/09/01
		NO 20001087 A	02/03/00
		NO 20005450 A	22/12/00
		NO 20005451 A	27/12/00
		PL 338982 A	04/12/00
		PL 343797 A	10/09/01
		PL 343801 A	10/09/01
		SE 9801526 D	00/00/00
		SK 14912000 A	11/06/01
		SK 14922000 A	11/06/01
		US 6245818 B	12/06/01
		US 6313136 B	06/11/01
		US 6313137 B	06/11/01
		WO 9955705 A	04/11/99